These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 33288583)

  • 1. Expression of FOXO4 Inhibits Cholangiocarcinoma Cell Proliferation
    Intuyod K; Chomwong S; Thongpon P; Vaeteewoottacharn K; Pairojkul C; Pinlaor P; Pinlaor S
    Anticancer Res; 2020 Dec; 40(12):6899-6905. PubMed ID: 33288583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of p53 and nuclear factor-kappaB signaling pathway for the induction of G1-phase cell cycle arrest of cholangiocarcinoma cell lines by isomorellin.
    Hahnvajanawong C; Ketnimit S; Pattanapanyasat K; Anantachoke N; Sripa B; Pinmai K; Seubwai W; Reutrakul V
    Biol Pharm Bull; 2012; 35(11):1914-25. PubMed ID: 22972485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabidiol exhibits potent anti-cancer activity against gemcitabine-resistant cholangiocarcinoma via ER-stress induction in vitro and in vivo.
    Pongking T; Thongpon P; Intuyod K; Klungsaeng S; Thanan R; Chaidee A; Charoenram N; Kongsintaweesuk S; Sakonsinsiri C; Vaeteewoottacharn K; Pinlaor S; Pinlaor P
    BMC Complement Med Ther; 2024 Aug; 24(1):325. PubMed ID: 39215312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin inhibits cholangiocarcinoma cell proliferation via cell cycle arrest in vitro and in vivo.
    Shi T; Gong J; Fujita K; Nishiyama N; Iwama H; Liu S; Nakahara M; Yoneyama H; Morishita A; Nonura T; Kobara H; Okano K; Suzuki Y; Masaki T
    Int J Oncol; 2021 Feb; 58(2):199-210. PubMed ID: 33491760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Modulation of FAK/PI3K/PDK1/AKT and FAK/p53 Pathways by Cucurbitacin B for the Antiproliferation Effect Against Human Cholangiocarcinoma Cells.
    Klungsaeng S; Kukongviriyapan V; Prawan A; Kongpetch S; Senggunprai L
    Am J Chin Med; 2020; 48(6):1475-1489. PubMed ID: 32907364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines.
    Tepsiri N; Chaturat L; Sripa B; Namwat W; Wongkham S; Bhudhisawasdi V; Tassaneeyakul W
    World J Gastroenterol; 2005 May; 11(18):2748-53. PubMed ID: 15884115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secreted cyclophilin A mediates G1/S phase transition of cholangiocarcinoma cells via CD147/ERK1/2 pathway.
    Obchoei S; Sawanyawisuth K; Wongkham C; Kasinrerk W; Yao Q; Chen C; Wongkham S
    Tumour Biol; 2015 Feb; 36(2):849-59. PubMed ID: 25296734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholangiocarcinoma cells express somatostatin receptor subtype 2 and respond to octreotide treatment.
    Zhao B; Zhao H; Zhao N; Zhu XG
    J Hepatobiliary Pancreat Surg; 2002; 9(4):497-502. PubMed ID: 12483273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E3 ubiquitin ligase FBW7α inhibits cholangiocarcinoma cell proliferation by downregulating c-Myc and cyclin E.
    Li M; Ouyang L; Zheng Z; Xiang D; Ti A; Li L; Dan Y; Yu C; Li W
    Oncol Rep; 2017 Mar; 37(3):1627-1636. PubMed ID: 28184929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-cancer activity of asiatic acid against human cholangiocarcinoma cells through inhibition of proliferation and induction of apoptosis.
    Sakonsinsiri C; Kaewlert W; Armartmuntree N; Thanan R; Pakdeechote P
    Cell Mol Biol (Noisy-le-grand); 2018 Jul; 64(10):28-33. PubMed ID: 30084792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin and atorvastatin as inhibitors of proliferation and inducers of apoptosis in human cholangiocarcinoma cells.
    Buranrat B; Senggunprai L; Prawan A; Kukongviriyapan V
    Life Sci; 2016 May; 153():41-9. PubMed ID: 27098189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luteolin arrests cell cycling, induces apoptosis and inhibits the JAK/STAT3 pathway in human cholangiocarcinoma cells.
    Aneknan P; Kukongviriyapan V; Prawan A; Kongpetch S; Sripa B; Senggunprai L
    Asian Pac J Cancer Prev; 2014; 15(12):5071-6. PubMed ID: 24998588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged oxidative stress down-regulates Early B cell factor 1 with inhibition of its tumor suppressive function against cholangiocarcinoma genesis.
    Armartmuntree N; Murata M; Techasen A; Yongvanit P; Loilome W; Namwat N; Pairojkul C; Sakonsinsiri C; Pinlaor S; Thanan R
    Redox Biol; 2018 Apr; 14():637-644. PubMed ID: 29169115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker.
    Chiang KC; Yeh TS; Wu RC; Pang JS; Cheng CT; Wang SY; Juang HH; Yeh CN
    Sci Rep; 2016 Oct; 6():36138. PubMed ID: 27782193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The transcription factor FOXO4 is down-regulated and inhibits tumor proliferation and metastasis in gastric cancer.
    Su L; Liu X; Chai N; Lv L; Wang R; Li X; Nie Y; Shi Y; Fan D
    BMC Cancer; 2014 May; 14():378. PubMed ID: 24886657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High glucose upregulates FOXM1 expression via EGFR/STAT3 dependent activation to promote progression of cholangiocarcinoma.
    Detarya M; Thaenkaew S; Seubwai W; Indramanee S; Phoomak C; Saengboonmee C; Wongkham S; Wongkham C
    Life Sci; 2021 Apr; 271():119114. PubMed ID: 33513399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest.
    Samukawa E; Fujihara S; Oura K; Iwama H; Yamana Y; Tadokoro T; Chiyo T; Kobayashi K; Morishita A; Nakahara M; Kobara H; Mori H; Okano K; Suzuki Y; Himoto T; Masaki T
    Int J Oncol; 2017 Dec; 51(6):1674-1684. PubMed ID: 29075786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment.
    Yothaisong S; Dokduang H; Anzai N; Hayashi K; Namwat N; Yongvanit P; Sangkhamanon S; Jutabha P; Endou H; Loilome W
    Tumour Biol; 2017 Mar; 39(3):1010428317694545. PubMed ID: 28347255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines.
    Asgar MA; Senawong G; Sripa B; Senawong T
    Int J Oncol; 2016 Jan; 48(1):409-20. PubMed ID: 26575528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting cancer-associated fibroblasts/tumor cells cross-talk inhibits intrahepatic cholangiocarcinoma progression via cell-cycle arrest.
    Mancarella S; Gigante I; Pizzuto E; Serino G; Terzi A; Dituri F; Maiorano E; Vincenti L; De Bellis M; Ardito F; Calvisi DF; Giannelli G
    J Exp Clin Cancer Res; 2024 Oct; 43(1):286. PubMed ID: 39415286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.